The value of dual-energy X-ray absorptiometry (DEXA) scans in monitoring HIV patients on protease inhibitors
Roff, G., McCarthy, M., Moore, C. and Mallal, S. (1999) The value of dual-energy X-ray absorptiometry (DEXA) scans in monitoring HIV patients on protease inhibitors. Nuclear Medicine Communications, 20 (4). pp. 403-404.
*Subscription may be required
With the introduction of HIV protease inhibitors into clinical practice in late 1996, the management and outcome of patients with HIV infection have been greatly improved. However, subsequent findings have found that these drugs produce some complicating peripheral lipodystrophy, hyperlipidaemia and insulin resistance. As part of a protocol to monitor these side-effects, whole-body DEXA scans are performed to demonstrate and quantify fat mass in various areas of the body. Follow-up scans are performed every 4-5 months. How beneficial are these scans to the management of the patients or are they lost among the myriad of other procedures?
|Publication Type:||Journal Article|
|Publisher:||Lippincott Williams and Wilkins|
|Item Control Page|